Definitive Contract 75N91024C00001
Award Date
2/15/24
Potential Completion Date
2/14/25
Potential Value
$355K
Federal Agency
National Cancer Institute
Awardee
Vcreate, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
West Menlo Park, CA 94025, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
52
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
STTR Phase I
Primary Consortia Member
Not listed
Similar Awards
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
This is a $300,000 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Coordination Pharmaceuticals Inc., a small business. The contract is for the detection, diagnosis, treatment, prevention, and research of pediatric cancers and/or rare cancers. It was awarded under a Small Business Innovation Research (SBIR) Concept Award Program, which is a "Phase 0" pilot program intended to encourage small businesses to develop innovative and...
This is a $355,000.00 Firm Fixed Price contract awarded by the National Institutes of Health (NIH) National Cancer Institute (NCI) to Petri Bio Inc., a small business, under the Small Business Innovation Research (SBIR) Phase I program. The contract is for the development of engineered microbial therapeutics for the treatment of heritable forms of glioma, a type of brain cancer. The work is focused on demonstrating technical feasibility and proof-of-concept for this therapeutic technology....
This is a $189,094.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Angiocrine Bioscience, Inc., a for-profit organization. The contract is for the "SBIR PHASE I LARGE SCALE PROPAGATION OF CANCER CELLS USING THE VERAVEC PLATFORM IN AN AUTOMATED CLOSED SYSTEM" and was set aside for small businesses. The contract has an ultimate completion date of July 21, 2016 and was awarded on September 22, 2015. This appears to be a Small Business...
<p>This is a $224,363 firm-fixed-price federal contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. government, to LP Therapeutics, Inc., a small business. The contract is for the development of nanoparticles to eradicate leukemia stem cells. The award has a completion date of July 31, 2015. This contract appears to be a standalone award, not associated with a larger contract vehicle.</p>
This is a $300,000.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Chimeron Bio Corporation, a small business manufacturer, for PHASE I THERAPEUTIC AWARD: CHIMERIC NANOPARTICLE DELIVERY OF AN SARNA-BASED CANCER VACCINE FOR FAMILIAL ADENOMATOUS POLYPOSIS under the Small Business Innovation Research (SBIR) Program. The contract is set aside for small businesses. This award is associated with a pre-solicitation opportunity that sought proposals...
This is a $1,499,588 firm fixed-price contract awarded by the National Cancer Institute to Creare LLC, a small business engineering R&D company, for the development of a Neuropsychological Assessment System for Cancer Patients (NASCP). Creare is collaborating with the Dartmouth-Hitchcock Clinic and Stanford Cancer Institute as clinical and research partners on this effort. The contract has a total small business set-aside designation. This work supports the National Cancer Institute's...
This $399,951 firm-fixed-price definitive contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to the small business Care Progress LLC. The contract supports the development of "BIOMARKERAWARE: A NOVEL SYSTEM TO IMPROVE PRECISION ONCOLOGY" under the NCI's Small Business Innovation Research (SBIR) program, which is a set-aside for small businesses. Care Progress LLC, a for-profit limited liability company, has previously...
<p>This is a Phase I Small Business Innovation Research (SBIR) contract awarded by the National Cancer Institute (NCI), a civilian agency, to Sibtech, Inc., a for-profit manufacturer, in the amount of $2,256,052.35. The contract is for the development of systemic radionuclide therapy targeted to VEGF receptors in tumor vasculature. The contract has a firm fixed price pricing type and an ultimate completion date of October 31, 2021. This contract is a set-aside for small businesses.</p>
This is a federal contract awarded by the National Cancer Institute (NCI), a civilian agency, to Pointcare Genomics Corp, a small minority-owned business, for research and development in biomedical basic research. The contract is a definitive, firm-fixed price contract valued at $299,961.00 and is part of the SBIR (Small Business Innovation Research) Program Phase I. The contract has a total small business set-aside designation and was awarded on September 22, 2015, with a completion date of...